Instrument Inactif

Communiqués Aerpio Pharmaceuticals

Actions

ARPO

US00810B1052

Communiqués

04/01/22	Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference	GL
23/11/21	Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)	GL
15/11/21	UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)	GL
19/10/21	Aerpio Pharmaceuticals : Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021	GL
27/08/21	AADI BIOSCIENCE, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/08/21	Aerpio Pharmaceuticals : Aadi Bioscience Corporate Overview	PU
23/08/21	Aerpio Pharmaceuticals : ASSET PURCHASE AGREEMENT (Form 8-K)	PU
23/08/21	AERPIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
18/08/21	Aerpio Pharmaceuticals : Submission of Matters to a Vote of Security Holders (Form 8-K)	PU
18/08/21	AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
11/08/21	AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
11/08/21	Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8-K)	PU
11/08/21	Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update	AQ
26/07/21	Aerpio Pharmaceuticals : Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa (Form 8-K)	PU
26/07/21	AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
07/06/21	Aerpio Pharmaceuticals : Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting	AQ
04/06/21	Aerpio Pharmaceuticals : Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting (Form 8-K)	PU
04/06/21	AERPIO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
04/06/21	Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting	GL
21/05/21	AERPIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerpio Pharmaceuticals, Inc. - ARPO	BU
20/05/21	Aerpio Pharmaceuticals : Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting (Form 8-K)	PU
20/05/21	AERPIO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
20/05/21	Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting	GL
17/05/21	AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
17/05/21	Aerpio Pharmaceuticals : Reports First Quarter 2021 Financial Results and Provides Business Update	AQ